-
EP3697399
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3697399
| EP3697399 - THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 21.07.2023 Database last updated on 02.11.2024 | |
| Former | Request for examination was made Status updated on 24.07.2020 | ||
| Former | The international publication has been made Status updated on 26.04.2019 | ||
| Former | unknown Status updated on 13.03.2018 | Most recent event Tooltip | 02.08.2024 | Change - divisional application(s) | published on 04.09.2024 [2024/36] | Applicant(s) | For all designated states IntraBio Ltd Summit House 170 Finchley Road London NW3 6BP / GB | [2020/43] |
| Former [2020/35] | For all designated states IntraBio Ltd 21 Waverton Street London W1J 5QN / GB | Inventor(s) | 01 /
FACTOR, Mallory 9 Hill Street London W1J 5LF / GB | [2020/35] | Representative(s) | Maiwald GmbH Elisenhof Elisenstraße 3 80335 München / DE | [N/P] |
| Former [2020/35] | Bühler, Dirk Maiwald Patentanwalts- und Rechtsanwaltsgesellschaft mbH Elisenhof Elisenstraße 3 80335 München / DE | Application number, filing date | 18708286.2 | 15.02.2018 | [2020/35] | WO2018US18420 | Priority number, date | US201762574137P | 18.10.2017 Original published format: US 201762574137 P | [2020/35] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019078915 | Date: | 25.04.2019 | Language: | EN | [2019/17] | Type: | A1 Application with search report | No.: | EP3697399 | Date: | 26.08.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 25.04.2019 takes the place of the publication of the European patent application. | [2020/35] | Search report(s) | International search report - published on: | EP | 25.04.2019 | Classification | IPC: | A61K31/13, A61P25/00, A61K31/495 | [2020/35] | CPC: |
A61K31/495 (EP,IL);
A61K31/198 (KR,RU,US);
A61K31/13 (EP,IL);
A61P25/00 (EP,IL);
A61P25/14 (RU);
A61P25/16 (KR,RU,US);
A61P25/28 (KR,RU,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/35] | Extension states | BA | 11.05.2020 | ME | 11.05.2020 | Validation states | MA | 11.05.2020 | MD | 11.05.2020 | TN | 11.05.2020 | Title | German: | THERAPEUTIKUM FÜR NEURODEGENERATIVE ERKRANKUNGEN | [2020/35] | English: | THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES | [2020/35] | French: | AGENTS THÉRAPEUTIQUES POUR MALADIES NEURODÉGÉNÉRATIVES | [2020/35] | Entry into regional phase | 11.05.2020 | National basic fee paid | 11.05.2020 | Designation fee(s) paid | 11.05.2020 | Examination fee paid | Examination procedure | 11.05.2020 | Examination requested [2020/35] | 11.05.2020 | Date on which the examining division has become responsible | 03.11.2020 | Amendment by applicant (claims and/or description) | 24.07.2023 | Despatch of a communication from the examining division (Time limit: M06) | 01.02.2024 | Reply to a communication from the examining division | Divisional application(s) | EP24192081.8 | Fees paid | Renewal fee | 11.05.2020 | Renewal fee patent year 03 | 12.02.2021 | Renewal fee patent year 04 | 14.01.2022 | Renewal fee patent year 05 | 03.01.2023 | Renewal fee patent year 06 | 03.01.2024 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [I]WO2011151685 (REKIK RAOUF [TN]); | by applicant | US9283181 |